Table 3.
Antiarrhythmic Drugs and Oral Anticoagulation Therapy
| PAF | LSPAF | |||||
|---|---|---|---|---|---|---|
| Preablation | Postablation | P Value | Preablation | Postablation | P Value | |
| Amiodarone | 93 (36%) | 28 (11%) | <0.0001 | 65 (52%) | 13 (10%) | <0.0001 |
| Sotalol | 42 (16%) | 21 (9%) | 0.005 | 10 (8%) | 6 (5%) | 0.30 |
| Propafenon | 100 (38%) | 20 (9%) | <0.0001 | 0 | 1 | — |
| Flecainide | 1 | 1 | — | 0 | 0 | — |
| Dronedarone | 0 | 2 | — | 0 | 1 | — |
| Warfarin | 247 (95%) | 82 (31%) | <0.0001 | 126 (100%) | 39 (31%) | <0.0001 |
Data shown as counts (proportions). LSPAF indicates long‐standing persistent atrial fibrillation; PAF, paroxysmal atrial fibrillation.
P=P‐value of χ2 test (preablation vs postablation).